Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext:NANO –– NASDAQ:NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023.
Related news for (NBTX)
- Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
- Nanobiotix annonce l’atteinte des conditions pour un paiement d’étape de développement de 20 M$ lié à l’étude mondiale de phase 3 en cours sur le cancer de la tête et du cou
- INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
- INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
- Voting Rights and Shares Capital of the Company